Paid Clinical Trials in Waterbury, CT
As of August 2026, 63 paid clinical trials are recruiting in Waterbury, Connecticut. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Waterbury offers studies at sites including Smilow Cancer Hospital-Waterbury Care Center for conditions such as Obesity, Breast Cancer, Overweight, Anatomic Stage II Breast Cancer AJCC v8. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Waterbury
Trials by drug in Waterbury
Filter results
Newly added in Waterbury
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
62 clinical trials
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Top Research Study Locations in Waterbury
Researchers run research studies in Waterbury, CT at 12 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Smilow Cancer Hospital-Waterbury Care Center | Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma | 38 |
| Chase Medical Research, LLC | Obesity, Overweight, Acute Migraine | 7 |
| Chase Medical Research LLC | Obesity, Overweight, Cardiovascular Disease | 5 |
| Smilow Cancer Hospital - Waterbury | Breast Cancer, Breast Neoplasms | 2 |
| ACCOMPLISH-2 Research Site | Chronic Weight Management, Obesity, Overweight | 1 |
| Chase Medical Research | Diabetic Peripheral Neuropathic Pain | 1 |
| Clinical Trial Site | High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension | 1 |
| MCCA | Problem Gambling | 1 |
| Retension Clinical Site | Uncontrolled Hypertension | 1 |
| Smilow Cancer Hospital Care Center - Waterbury | Metastatic Breast Cancer | 1 |
| Smilow Cancer Hospital Care center at Waterbury | Breast Cancer, HER2-positive Breast Cancer | 1 |
| St. Mary's Hospital | Breast Cancer | 1 |
Active & Upcoming Studies in Waterbury (2026)
Recruiting trials in Waterbury grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (39 active studies)
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · Phase 3 · NRG Oncology
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study · Phase 2 · SWOG Cancer Research Network
Diabetes & metabolic (6 active studies)
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) · Phase 3 · Amgen
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) · Phase 3 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Neurology & pain (3 active studies)
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine · Phase 3 · Kallyope Inc.
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine · Phase 3 · Kallyope Inc.
Cardiovascular (3 active studies)
- A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension · Phase 2 · Retension Pharmaceuticals. Inc.
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease · Phase 3 · Alnylam Pharmaceuticals
Common conditions studied in Waterbury
- Obesity (6 active studies)
- Breast Cancer (5 active studies)
- Overweight (5 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Stage IV Lung Cancer AJCC v8 (4 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
Leading research sponsors in Waterbury
- SWOG Cancer Research Network
- National Cancer Institute (NCI)
- NRG Oncology
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Waterbury?
There are approximately 63 recruiting clinical trials in Waterbury, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Waterbury pay participants?
Most recruiting trials in Waterbury compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Waterbury?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Waterbury?
The most common conditions under active study in Waterbury include Obesity (6), Breast Cancer (5), Overweight (5), Anatomic Stage II Breast Cancer AJCC v8 (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Waterbury?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Waterbury on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Waterbury?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Waterbury?
Recruiting research sites in Waterbury include Smilow Cancer Hospital-Waterbury Care Center, Chase Medical Research, LLC, Chase Medical Research LLC, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Waterbury right now?
The largest active categories in Waterbury are Cancer & tumors (39), Diabetes & metabolic (6), Neurology & pain (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.